Dihydromyricetin compositions
The disclosure provides dermal patch formulations that include a pharmaceutically active agent, such as one or more cannabinoids. The formulations can include dihydromyricetin for the purpose of increasing the flux of the pharmaceutical agent into human skin.
1. A monolithic patch that comprises polyisobutylene (PIB) adhesive, with the penetration enhancer dihydromyricetin, and with 15% of cannabidiol (CBD), wherein the construction comprises an adhesive layer attached to a backing, and wherein the monolithic patch is capable of delivering CBD at a net flux of at least 195 micrograms CBD per square centimeter of skin over a period of 24 hours, as compared to a control net flux of about 155 micrograms CBD per square centimeter of skin over a period of 24 hours for a control monolithic patch that does not contain any dihydromyricetin wherein the dihydromyricetin concentration is about 0.5% about 1.0%, about 2.0%, about 3.0%, about 4.0%, or about 5.0% dihydromyricetin.
2. The monolithic patch of claim 1 , wherein the backing comprises polyethylene foam film.
3. The monolithic patch of claim 2 that does not contain any type of overlay that is in addition to the polyethylene foam film.
4. The monolithic patch of claim 1 , wherein the cannabinoid flux is measured or is measurable with a Franz diffusion cell and human cadaver skin.
5. The monolithic patch of claim 1 that does not comprise any penetration enhancer aside from dihydromyricetin.
6. The monolithic patch of claim 1 that does not comprise any combination of azone, oleic acid, a terpene, and ethanol.
7. The monolithic patch of claim 1 that does not comprise one or more of azone, oleic acid, a terpene, and ethanol.
8. The monolithic patch of claim 1 , wherein the only cannabinoid present is CBD.